scholarly journals Additive/Synergistic Effects of Interleukin-6 and Interleukin-10 on the Proliferation of Human Myeloma Cells

2015 ◽  
Vol 1 (3) ◽  
pp. 74-78
Author(s):  
Eva Kovacs-Benke ◽  
2013 ◽  
Vol 3 (6) ◽  
pp. e120-e120 ◽  
Author(s):  
D Chiron ◽  
S Maïga ◽  
S Surget ◽  
G Descamps ◽  
P Gomez-Bougie ◽  
...  

2007 ◽  
Vol 85 (1) ◽  
pp. 49-58 ◽  
Author(s):  
Shangqin Liu ◽  
Ken-ichiro Otsuyama ◽  
Zi Ma ◽  
Saeid Abroun ◽  
Karim Shamsasenjan ◽  
...  

Blood ◽  
1998 ◽  
Vol 91 (12) ◽  
pp. 4727-4737 ◽  
Author(s):  
Cosette Rebouissou ◽  
John Wijdenes ◽  
Patrick Autissier ◽  
Karin Tarte ◽  
Valerie Costes ◽  
...  

Agonist antihuman gp130 transducer monoclonal antibodies (MoAbs) were used in SCID mice to grow myeloma cells whose survival and proliferation is dependent on gp130 transducer activation. The agonist anti-gp130 MoAbs neither bound to murine gp130 nor activated murine cells and, as a consequence, did not induce interleukin-6 (IL-6)–related toxicities in mice. They have a 2-week half-life in vivo when injected in the peritoneum. The agonist antibodies made possible the in vivo growth of exogenous IL-6–dependent human myeloma cells as well as that of freshly explanted myeloma cells from 1 patient with secondary plasma cell leukemia. Tumors occurred 4 to 10 weeks after myeloma cell graft and weighed 3 to 5 g. They grew as solid tumors in the peritoneal cavity and metastasized to the different peritoneal organs: liver, pancreas, spleen, and intestine. Tumoral cells were detected in blood and bone marrow of mice grafted with the XG-2 myeloma cells. Tumoral cells grown in SCID mice had kept the phenotypic characteristics of the original tumoral cells and their in vitro growth required the presence of IL-6 or agonist anti-gp130 MoAbs. Myeloma cells from 4 patients with medullary involvement persisted for more than 1 year as judged by detectable circulating human Ig. However, no tumors were detected, suggesting a long-term survival of human myeloma cells without major proliferation. These observations paralleled those made in in vitro cultures as well as the tumor growth pattern in these patients. This gp130 transducer-dependent SCID model of multiple myeloma should be useful to study various therapeutical approaches in multiple myeloma in vivo.


2002 ◽  
Vol 116 (4) ◽  
pp. 787-795 ◽  
Author(s):  
Takemi Otsuki ◽  
Kenichiro Yata ◽  
Haruko Sakaguchi ◽  
Junichi Kurebayashi ◽  
Yoshinobu Matsuo ◽  
...  

Blood ◽  
2004 ◽  
Vol 103 (6) ◽  
pp. 2291-2298 ◽  
Author(s):  
Saeid Abroun ◽  
Hideaki Ishikawa ◽  
Naohiro Tsuyama ◽  
Shangqin Liu ◽  
Fu-Jun Li ◽  
...  

Abstract Interleukin-6 (IL-6) is a growth and antiapoptotic factor for human myeloma cells. The autocrine loop and increased expression of the growth factor receptors have been postulated as the mechanisms of tumorigenesis. Here we show that IL-6 stimulation induced the phosphorylation of insulin-like growth factor-I (IGF-I) receptors in a human myeloma cell line, NOP2, highly expressing IL-6 receptor α (IL-6Rα) and in the IL-6Rα–transfected U266 cell line. IL-6–dependent complex formation of IL-6Rα with IGF-I receptor β was found in NOP2 where IL-6Rα colocalized with IGF-I receptors at lipid rafts. Moreover, the IL-6–induced phosphorylation of IGF-I receptor β was not blocked by a Janus kinase 2 (Jak2) inhibitor. In addition to the activation of the signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2, IL-6 stimulation led to the activation of Akt, presumably following the phosphorylation of IGF-I receptors. Thus, our results suggest that in NOP2, IL-6Rα and IGF-I receptors exist on the plasma membrane in close proximity, facilitating the efficient assembly of 2 receptors in response to IL-6. The synergistic effects of highly expressed IL-6Rα on IGF-I receptor–mediated signals provide a novel insight into the Jak-independent IL-6 signaling mechanism of receptor cross-talk in human myeloma cells.


2003 ◽  
Vol 78 (2) ◽  
pp. 95-105 ◽  
Author(s):  
Hideaki Ishikawa ◽  
Naohiro Tsuyama ◽  
Michio M. Kawano

Oncogene ◽  
2002 ◽  
Vol 21 (16) ◽  
pp. 2584-2592 ◽  
Author(s):  
Yue Dan Wang ◽  
John De Vos ◽  
Michel Jourdan ◽  
Guilhem Couderc ◽  
Zhao-Yang Lu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document